Blockade of glucocorticoid excess at the tissue level: inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 as a therapy for type 2 diabetes.
Fotsch
Christopher
C
Department of Medicinal Chemistry, Amgen Inc, Thousand Oaks, California 91320, USA.
Wang
Minghan
M
D042842:11-beta-Hydroxysteroid Dehydrogenases / Q000037:antagonists & inhibitors* / Q000502:physiology; D000818:Animals; D002229:Carbenoxolone / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006034:Glycyrrhetinic Acid / Q000627:therapeutic use; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D009765:Obesity / Q000201:enzymology
D004791:Enzyme Inhibitors; D005938:Glucocorticoids; D042842:11-beta-Hydroxysteroid Dehydrogenases; D002229:Carbenoxolone; D006034:Glycyrrhetinic Acid